Table 3.

Recommendations for stereotactic body radiation therapy (SBRT) in breast cancer patients with extracranial oligometastatic disease (OMD)

Classification of OMD	Subclassification of OMD	Subclassification of OMD	Subclassification of OMD	Clinical presentation	DEGRO recommendation for SBRTb	Level of evidence
Genuine oligometastatic disease	De novo oligometastatic disease	Synchronous oligometastatic disease		1 lesion, bone 1 lesion, elsewhere 2–5 lesions	++ + ±a	4 4 4
		Metachronous oligometastatic disease	Metachronous oligorecurrence	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	++ + ±a	4 4 4
			Metachronous oligoprogression	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	++ + ±a	4 4 4
	Repeat oligometastatic disease	Repeat oligorecurrence		1 lesion, bone 1 lesion, elsewhere 2–5 lesions	No recommendation	Insufficient evidence
		Repeat oligometastatic disease	Repeat oligopersistence	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	No recommendation	Insufficient evidence
			Repeat oligoprogression	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	±a ±a ±a	5 5 5
Induced oligometastatic disease		Induced oligorecurrence		1 lesion, bone 1 lesion, elsewhere 2–5 lesions	No recommendation	Insufficient evidence
		Induced oligometastatic disease	Induced oligopersistence	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	No recommendation	Insufficient evidence
			Induced oligoprogression	1 lesion, bone 1 lesion, elsewhere 2–5 lesions	±a ±a ±a	4 4 4

For definition of oligometastatic disease (OMD), see Guckenberger et al. [12].

^abetter results in patients with long progression-free interval, no visceral lesions, or ≤ 3 lesions

^bif all lesions are amenable for local ablative stereotactic body radiation therapy (SBRT)

++ SBRT should be performed, + SBRT should be considered, ± SBRT may be considered in favorable cases (see^a)